Bruna Pellini

926 total citations
40 papers, 489 citations indexed

About

Bruna Pellini is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Bruna Pellini has authored 40 papers receiving a total of 489 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Pulmonary and Respiratory Medicine, 22 papers in Oncology and 17 papers in Cancer Research. Recurrent topics in Bruna Pellini's work include Lung Cancer Treatments and Mutations (24 papers), Cancer Genomics and Diagnostics (14 papers) and Lung Cancer Research Studies (10 papers). Bruna Pellini is often cited by papers focused on Lung Cancer Treatments and Mutations (24 papers), Cancer Genomics and Diagnostics (14 papers) and Lung Cancer Research Studies (10 papers). Bruna Pellini collaborates with scholars based in United States, Brazil and Spain. Bruna Pellini's co-authors include Misty Dawn Shields, Julian A. Marin‐Acevedo, Aadel A. Chaudhuri, Jeffrey J. Szymanski, Pradeep S. Chauhan, Kevin Chen, Peter K. Harris, Nicholas P. Semenkovich, Noah Earland and Alberto Chiappori and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Bruna Pellini

35 papers receiving 483 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bruna Pellini United States 14 261 254 192 119 60 40 489
Kyrillus S. Shohdy Egypt 12 213 0.8× 197 0.8× 114 0.6× 88 0.7× 59 1.0× 39 440
Fawaz Almutairi Saudi Arabia 7 232 0.9× 130 0.5× 114 0.6× 68 0.6× 48 0.8× 22 372
Katherine A. Scilla United States 11 290 1.1× 363 1.4× 162 0.8× 136 1.1× 47 0.8× 25 583
Lingzhi Hong United States 12 238 0.9× 216 0.9× 115 0.6× 213 1.8× 45 0.8× 28 487
Andri Papakonstantinou Sweden 11 198 0.8× 237 0.9× 151 0.8× 87 0.7× 36 0.6× 33 419
Angel Qin United States 12 201 0.8× 343 1.4× 122 0.6× 178 1.5× 45 0.8× 33 561
Ashish Sangal United States 8 208 0.8× 339 1.3× 132 0.7× 67 0.6× 60 1.0× 19 464
Yasser Ged United States 12 361 1.4× 212 0.8× 169 0.9× 244 2.1× 87 1.4× 59 549
Vincenzo Emanuele Chiurì Italy 12 456 1.7× 478 1.9× 189 1.0× 213 1.8× 67 1.1× 35 703
Timothy Kwang Yong Tay Singapore 11 123 0.5× 154 0.6× 155 0.8× 107 0.9× 56 0.9× 38 423

Countries citing papers authored by Bruna Pellini

Since Specialization
Citations

This map shows the geographic impact of Bruna Pellini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruna Pellini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruna Pellini more than expected).

Fields of papers citing papers by Bruna Pellini

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruna Pellini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruna Pellini. The network helps show where Bruna Pellini may publish in the future.

Co-authorship network of co-authors of Bruna Pellini

This figure shows the co-authorship network connecting the top 25 collaborators of Bruna Pellini. A scholar is included among the top collaborators of Bruna Pellini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruna Pellini. Bruna Pellini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Leighl, Natasha B., Nofisat Ismaila, Greg Andrew Durm, et al.. (2025). Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2024.3. Journal of Clinical Oncology. 43(10). e17–e30. 5 indexed citations
2.
Lenz, Gabriel, Mariah Malak Bilalaga, Nelly Müller, et al.. (2025). Chemotherapy Plus Anti-PD-1 or Anti-PD-L1 in Advanced PD-L1–Negative Squamous Cell Lung Carcinoma: A Systematic Review and Meta-Analysis. Clinical Lung Cancer. 26(6). e361–e373.
3.
Walls, Gerard, Bruna Pellini, & Aadel A. Chaudhuri. (2024). Circulating tumor DNA kinetics: A future tool for radiation therapy personalization in lung cancer?. SHILAP Revista de lepidopterología. 6. 100160–100160. 2 indexed citations
4.
Vince, M.A., et al.. (2024). Real-world comparison of the efficacy and safety of atezolizumab versus durvalumab in extensive-stage small cell lung cancer. Lung Cancer. 198. 107999–107999. 3 indexed citations
5.
Desai, Aakash, et al.. (2024). ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung Cancer. Cancers. 16(5). 940–940. 18 indexed citations
6.
Pellini, Bruna, Derek W. Brown, Jason D. Hughes, et al.. (2024). Computational Variant Origin Prediction (VOP) to distinguish germline, tumor somatic, and Clonal Hematopoiesis (CH) variants in Liquid Biopsy (LBX). Repository of Digital Objects for Teaching Research and Culture (University of Valencia). 5. 100242–100242.
7.
Thapa, Ram, Michael Shafique, Andreas Saltos, et al.. (2023). Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation. Journal of Thoracic Disease. 15(11). 6115–6125. 4 indexed citations
8.
9.
Pellini, Bruna, Russell W. Madison, Ole Gjoerup, et al.. (2023). Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research. 29(22). 4596–4605. 25 indexed citations
10.
Tian, Yijun, Paul A. Stewart, Yury O. Núñez López, et al.. (2023). Detectable Lipidomes and Metabolomes by Different Plasma Exosome Isolation Methods in Healthy Controls and Patients with Advanced Prostate and Lung Cancer. International Journal of Molecular Sciences. 24(3). 1830–1830. 8 indexed citations
11.
Semenkovich, Nicholas P., Jeffrey J. Szymanski, Noah Earland, et al.. (2023). Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA. Journal for ImmunoTherapy of Cancer. 11(6). e006284–e006284. 36 indexed citations
12.
Samson, Pamela, Shahed N. Badiyan, Gregory Vlacich, et al.. (2023). Circulating Tumor DNA for Early Risk Stratification of Oligometastatic Lung Cancer. International Journal of Radiation Oncology*Biology*Physics. 117(2). S29–S30. 1 indexed citations
13.
Shields, Misty Dawn, et al.. (2022). Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer. Current Treatment Options in Oncology. 23(8). 1104–1120. 10 indexed citations
14.
Huang, Jinyong, Mingxiang Teng, İbrahim Halil Şahin, et al.. (2021). Cancer Detection and Classification by CpG Island Hypermethylation Signatures in Plasma Cell-Free DNA. Cancers. 13(22). 5611–5611. 11 indexed citations
15.
Devarakonda, Siddhartha, Bruna Pellini, Haeseong Park, et al.. (2021). A phase II study of everolimus in patients with advanced solid malignancies with TSC1, TSC2, NF1, NF2 or STK11 mutations. Journal of Thoracic Disease. 13(7). 4054–4062. 15 indexed citations
16.
Pellini, Bruna, et al.. (2020). Liquid Biopsies Using Circulating Tumor DNA in Non-Small Cell Lung Cancer. Thoracic surgery clinics/Thorac. surg. clin.. 30(2). 165–177. 24 indexed citations
17.
Graudenz, Márcia Silveira, et al.. (2019). Claudins 1, 3, 4, 7 and 10-year survival in triple-negative breast tumors. 29(2). 71–78. 3 indexed citations
18.
Jacobs, Miriam T., Bruna Pellini, Ramon U. Jin, et al.. (2019). The use of ruxolitinib for acute graft-versus-host disease developing after solid organ transplantation. American Journal of Transplantation. 20(2). 589–592. 13 indexed citations
19.
Pellini, Bruna, et al.. (2016). Metastatic Hepatoid Carcinoma of the Pancreas: First Description of Treatment With Capecitabine and Temozolomide. The American Journal of the Medical Sciences. 353(6). 610–612. 14 indexed citations
20.
Graudenz, Márcia Silveira, et al.. (2014). Expression of cancer stem cell markers in basal and penta-negative breast carcinomas – A study of a series of triple-negative tumors. Pathology - Research and Practice. 210(7). 432–439. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kyrillus S. Shohdy Breakdown of academic impact, for papers by Fawaz Almutairi Breakdown of academic impact, for papers by Katherine A. Scilla Breakdown of academic impact, for papers by Lingzhi Hong Breakdown of academic impact, for papers by Andri Papakonstantinou Breakdown of academic impact, for papers by Angel Qin Breakdown of academic impact, for papers by Ashish Sangal Breakdown of academic impact, for papers by Yasser Ged Breakdown of academic impact, for papers by Vincenzo Emanuele Chiurì Breakdown of academic impact, for papers by Timothy Kwang Yong Tay
Rankless by CCL
2026